Samina Khan
Net worth: 7 M $ as of 2023-09-29
Profile
Presently, Samina Khan holds the position of Chief Medical Officer & Senior Vice President of Reata Pharmaceuticals, Inc. Dr. Khan previously was Vice President-Cardio-Renal Programs at Quark Pharmaceuticals, Inc.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
2023-05-15 | 39,491 ( 0.12% ) | 7 M $ | 2023-09-29 |
Former positions of Samina Khan
Companies | Position | End |
---|---|---|
REATA PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 2023-09-25 |
Quark Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | Corporate Officer/Principal | 2017-03-31 |
Tufts University School of Medicine | Corporate Officer/Principal | - |
Training of Samina Khan
Brandeis University | Masters Business Admin |
Harvard Medical School | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 2 |
---|---|
Reata Pharmaceuticals, Inc.
Reata Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by J. Warren Huff in 2002 and is headquartered in Plano, TX. | Health Technology |
Quark Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | Health Technology |
- Stock Market
- Insiders
- Samina Khan